Table 3.
Comparison of AMR in pathogenic E. coli and Salmonella spp
| Antibiotic resistance type | Family |
Number of isolates (%; CI) |
p-value | |
|---|---|---|---|---|
| E. coli (n = 43) | Salmonella spp. (n = 47) | |||
| Ampicillin | β-lactams | 24 (55.8; 39.9–70.9) | 11 (23.4;12.3–38.0) | 0.003* |
| Amoxycillin | 38 (88.4;74.9–96.1) | 21 (44.7;30.2–59.9) | < 0.001* | |
| Amoxycillin clavulanic acid | Modified penicillins | 1 (2.3;0.0–12.3) | 10 (21.3;10.7–35.7) | 0.016* |
| Ciprofloxacin | Quinolones | 14 (32.6; 19.1–48.5) | 26 (55.3;40.1–69.8) | 0.05 |
| Nalidixic acid | 28 (65.1;49.1–79.0) | 21 (44.7;30.2–59.9) | 0.083 | |
| Gentamicin | Aminoglycosides | 11 (25.6;13.5–41.2) | 8 (17.0;7.7–30.8) | 0.462 |
| Neomycin | 19 (44.2;29.1–60.1) | 14 (29.8;17.3–44.9) | 0.231 | |
| Cefazolin | Cephalosporins (1st, 2nd, 3rd) | 36 (83.7;69.3–93.2) | 20 (42.5;20.3–57.8) | < 0.001* |
| Cefoxitin | 0 (0.0;0.0–8.2) | 1 (2.1;0.0–11.3) | 1.000 | |
| Cefuroxime | 3 (7.0;1.5–19.1) | 9 (19.1;9.2–33.3) | 0.166 | |
| Cefotaxime | 9 (20.9;10.0–36.0) | 13 (27.7;15.6–42.6) | 0.620 | |
| Ceftriaxone | 3 (7.0;1.5–19.1) | 3 (6.4; 1.3–17.5) | 1.000 | |
| Imipenem | Carbapenems | 5 (11.6;3.9–25.1) | 7 (14.9;6.2–28.3) | 0.885 |
| Tetracycline | Tetracyclines | 37 (86.0;72.1–94.7) | 1 (2.1;0.0–11.3) | < 0.001* |
| Chloramphenicol | Phenicols | 15 (34.9;21.0–51.0) | 0 (0.0;0.0–7.6) | < 0.001* |
| Trimethoprim sulphamethoxazole | Potentiated sulphonamides | 30 (69.8;53.9–82.8) | 2 (4.3;0.0–14.5) | < 0.001* |
| MDR (≥ 3 antimicrobials) | 38 (88.4;74.9–96.1) | 25 (53.2;38.1–67.9) | <0.001* | |
Statistical analysis: X2 test with Yate’s continuity correction; CI-Confidence Interval.
* Statistically significant.